Kevin Weber
About Kevin Weber
Kevin D. Weber (age 67) is an independent director of Biofrontera Inc. (BFRI) who joined the Board in March 2022; he is an experienced pharmaceutical executive with 30+ years in commercialization and product marketing across dermatology, pain, metabolic and respiratory indications, and holds a B.S. in Business Administration from Western Michigan University . He retired in 2022 as a Principal at Skysis, previously served as CEO of Paraffin International, and held senior roles at Depomed, Hyperion Therapeutics, and Medicis Pharmaceuticals; he served on the supervisory board of Biofrontera AG from 2016–2021 and on boards of the American Academy of Pain Medicine Foundation, American Chronic Pain Association, and Arizona Bioindustry Association . He is currently a Class II director with a term expiring at the 2026 annual meeting .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Skysis (biotech brand management) | Principal | Retired 2022 | Commercial strategy; product marketing expertise |
| Paraffin International | Chief Executive Officer | Not disclosed | Operational leadership |
| Depomed; Hyperion Therapeutics; Medicis Pharmaceuticals | Senior executive and marketing roles | Not disclosed | Commercialization across multiple therapeutic areas |
| Biofrontera AG | Supervisory Board member | 2016–2021 | Oversight at former parent; sector network |
| American Academy of Pain Medicine Foundation; American Chronic Pain Association; Arizona Bioindustry Association | Director | Not disclosed | Non-profit governance in pain/biotech ecosystems |
External Roles
| Organization | Role | Status | Notes |
|---|---|---|---|
| Public company boards (current) | — | None disclosed | No current public directorships disclosed for Weber |
Board Governance
- Committee assignments: Audit Committee member; Nominating & Corporate Governance Committee member; Compensation Committee Chair .
- Independence: Board determined Weber satisfies Nasdaq independence standards; he also meets heightened independence for Audit and Compensation Committee service .
- Attendance: In 2024, there were 39 Board meetings; all directors attended at least 90% of Board and applicable committee meetings; four directors attended the 2024 Annual Meeting .
- Committee activity: Audit Committee held four meetings in 2024; Nominating & Corporate Governance held two meetings in 2024 .
- Board structure: Classified board (three classes); Weber is Class II (term ends at 2026 annual meeting); no Lead Independent Director designated; CEO and Chair roles combined .
Fixed Compensation
| Component (2024) | Amount | Notes |
|---|---|---|
| Fees Earned or Paid in Cash | $59,250 | Actual cash compensation received for 2024 |
| Policy – Board annual retainer | $40,250 | Applies to non-employee directors |
| Policy – Audit Committee member | $8,000 | Weber is a member |
| Policy – Compensation Committee chair | $9,000 | Weber is Chair |
| Policy – Nominating & Corporate Governance member | $5,000 | Weber is a member |
Performance Compensation
| Component (2024) | Amount | Grant Detail |
|---|---|---|
| Option Awards (fair value) | $15,720 | Director equity award expense; grant specifics (shares/strike) not separately disclosed for directors |
| Performance Metrics Tied to Director Compensation | Disclosed? | Notes |
|---|---|---|
| TSR, revenue/EBITDA targets, ESG, etc. | Not disclosed | Director comp appears retainer + equity; no performance metrics disclosed |
Other Directorships & Interlocks
| Entity | Nature | Relevance |
|---|---|---|
| Biofrontera AG (prior) | Weber served on Supervisory Board (2016–2021) | Historical affiliation with former parent; not current |
| Biofrontera AG (current interlock via another director) | Director Heikki Lanckriet currently serves as a director of Biofrontera AG; Series D Preferred issued to Biofrontera AG | Potential information flow via another director; Company notes Lanckriet’s dual role in proposals |
Expertise & Qualifications
- 30+ years’ executive commercialization experience with emphasis on product marketing in dermatology and other therapeutic areas; prior CEO and senior roles across multiple biopharma companies .
- Demonstrated board governance experience at Biofrontera AG and multiple non-profits in pain and biotech .
- Education: B.S., Business Administration, Western Michigan University .
- Audit Committee literacy: Audit members must understand financial statements; Board designated audit financial expert is Borer; Weber meets independence requirements for audit/comp committees .
Equity Ownership
| As of | Shares Beneficially Owned | % of Outstanding | Options Exercisable and RSUs Vesting within 60 Days |
|---|---|---|---|
| July 18, 2025 | — | <1% (denoted “*”) | 21,100 |
Notes: “*” indicates less than 1% beneficial ownership; table shows directors’ and NEOs’ ownership and near-term vesting/exercisability .
Governance Assessment
- Strengths: Independent director with extensive commercialization background; chairs Compensation Committee and serves on Audit and Nominating & Governance, signaling active engagement; Board reports at least 90% attendance and active committee schedules (Audit: 4 meetings; Nominating & Governance: 2) in 2024 .
- Alignment: Weber’s 2024 director pay mix is primarily cash ($59,250) with modest equity option award value ($15,720), and no direct share ownership reported as of July 18, 2025 though 21,100 options/RSUs were near-term exercisable/vesting; overall personal ownership appears limited (<1%), which may temper alignment with long-term shareholders .
- Compensation governance: Compensation Committee responsibilities include executive pay oversight, incentive plan administration, and director remuneration; presence of an updated Nasdaq-compliant clawback policy for executives (Oct 2, 2023) enhances pay-for-performance governance, though clawbacks apply to covered executives rather than directors .
- Oversight risks and potential red flags:
- Combined CEO/Chair and absence of a Lead Independent Director can weaken independent oversight and board challenge culture .
- Capital structure complexity and reliance on stockholder approvals for Series C/D Preferred voting and conversion reflect financing stress; while not a Weber-specific conflict, it increases governance complexity around investor rights and could affect board bandwidth; company disclosed Lanckriet’s dual role with Biofrontera AG (holder of Series D) as a specific interest consideration .
- No director stock ownership guidelines or pledging/hedging disclosures specific to Weber were found; beneficial ownership table does not indicate pledging, which is positive, but lack of meaningful ownership is a mild alignment concern .
- Overall: Weber appears independent, highly experienced, and engaged across key committees, with particular influence as Compensation Committee Chair. Board-level structural issues (CEO/Chair combined; no lead independent director) and limited disclosed personal share ownership are notable considerations for investor confidence and governance quality .
RED FLAGS
- No Lead Independent Director; CEO/Chair combined .
- Limited personal share ownership (<1% beneficial ownership; no common shares reported) .
- Governance complexity around preferred stock voting/convertibility and related interlock via another director (Lanckriet) tied to Biofrontera AG as Series D holder .